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Background: The aim of this study was to translate the EORTC quality of life questionnaire for brain cancer, the
QLQ-BN20, into Persian, and to evaluate its psychometric properties when used among brain cancer patients in
Iran.
Methods: A standard backward and forward translation procedure was used to generate the Persian language
version of the QLQ-BN20. The QLQ-BN20 was administered together with the QLQ-C30 to 194 patients diagnosed
with primary brain cancer. Multitrait scaling and confirmatory factor analysis (CFA) were used to evaluate the
hypothesized scale structure of the questionnaire. Internal consistency reliability was estimated with Cronbach’s
alpha. The ability of the QLQ-BN20 to distinguish between patient subgroups formed on the basis of performance
status and cognitive status was evaluated, as was the responsiveness of the questionnaire to changes in
performance status over time.
Results: Multitrait scaling and CFA results confirmed the hypothesized scale structure. The measurement model
was consistent across men and women. Internal consistency reliability of the multi-item scales ranged from 0.74 to
0.89. The QLQ-BN20 distinguished clearly between patients with relatively good versus poor performance and
cognitive status, and changes in scores over time reflected changes observed in performance status ratings.
Conclusions: These results support the validity and reliability of the QLQ-BN20 for use among Iranian patients
diagnosed with primary brain cancer. Future studies should examine the psychometrics of the questionnaire when
used in patients with brain metastasis.
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It is estimated that 22,020 patients are diagnosed annu-
ally with brain cancer in the United States [1]. In Iran,
brain cancer is the 11th most common cancer, with an
annual incidence rate of approximately 550 cases for
males and 800 for females [2]. Although brain cancer is
relatively rare, it is a disease with serious symptoms and
a poor prognosis. [1,3]. The 5-year relative survival rate
is 36% [1].
There is no definite cure for patients with brain can-
cer. Therefore, the primary aim of treatment is to* Correspondence: Pakpour_Amir@yahoo.com
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distribution, and reproduction in any mediumprolong the patient's life and to palliate symptoms [4].
The treatment for the most common brain tumors, gli-
omas, includes neurosurgery, followed by adjuvant
radiotherapy, chemotherapy or combined chemora-
diotherapy. All of these treatments may cause significant
complications or have toxic side-effects [5,6]. Therefore,
in order to select the best treatment for a specific patient
it is necessary to take into consideration the stage of the
disease, any risk associated with the given treatment and
the patient's general health. An assessment of patient-
reported outcomes, and more specifically health-related
quality of life (HRQOL), is very important in this
respect.
Two well-known, generic questionnaires for assessing
the HRQOL of patients with cancer include The Euro-
pean Organization for Research and Treatment of Can-
cer Core Questionnaire (the EORTC QLQ-C30) and theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Khoshnevisan et al. Health and Quality of Life Outcomes 2012, 10:54 Page 2 of 8
http://www.hqlo.com/content/10/1/54Functional Assessment of Cancer Therapy-General
(FACT-G) [7,8]. These generic questionnaires are applic-
able to all types of patients with cancer. Both the
EORTC and the FACT measurement systems supple-
ment their core questionnaire with condition-specific
questionnaires designed to capture functional limitations
and symptoms experienced by specific populations of
patients. Both the EORTC and the FACT systems have
developed questionnaires specific to brain cancer. The
EORTC brain cancer-specific questionnaire, the QLQ-
BN20, has been validated and has been translated into a
number of primarily European languages [9,10]. The aim
of the present study was to translate the QLQ-BN20 into
the dominant language in Iran, Persian (spoken by ap-
proximately two-thirds of the population), and to gener-
ate psychometric data regarding the questionnaires
reliability and validity when used among Iranian brain
cancer patients.
Methods
Translation of the QLQ-BN20
The QLQ-BN20 questionnaire contains 20 items orga-
nized into four scales; future uncertainty (3 items), visual
disorder (3 items); motor dysfunction (3 items); and
communication deficit (3 items), and seven single items
(headaches, seizures, drowsiness, hair loss, itchy skin,
weakness of legs, and bladder control) [9,10]. All items
are rated on a four-point Likert-type scale (‘not at all’, ‘a
little’, ‘quite a bit’ and ‘very much’), and are linearly trans-
formed to a 0-100 scale, with higher scores indicating
more severe symptoms [11].
We obtained permission from the EORTC Quality of
Life Department to generate the Iranian version of the
QLQ-BN20. The aim of the translation procedure was
to provide an Iranian version of the questionnaire that
was conceptually equivalent to the original English lan-
guage version.
We used the standard EORTC translation procedures
[12]. Briefly, two trained bilingual Iranians independently
translated the QLQ-BN20 into Persian. A specialized
translator (project manager; AHP) compared these two
versions, evaluated the level of difficulty in terms of
translation as well as the equivalence of each item and
response scale. The translators compared their transla-
tions, reconciled their discrepancies and arrived at a uni-
fied Persian version of the questionnaire. Subsequently,
the provisional Persian version was independently trans-
lated back into U.S. English by two additional translators
who were native English speakers. The Project Manager
compared the English translations with the original
questionnaire, and any discrepancies between the back-
translations were resolved with the translators. This
process went through two iterations, and the documen-
tation was reviewed by the EORTC Quality of LifeGroup. The resulting Persian version of the QLQ-BN20
was administered to 10 brain tumor patients (6 women
and 4 men; age range = 28–69 years). All patients were
able to complete the questionnaire without assistance,
and reported that the questions were clear and easy to
complete.
Validation of the Persian version of the QLQ-BN20
Study participants were patients with primary brain can-
cer who had been referred to Shariati Hospital and the
Cancer Institute of Iran in Tehran. These centers are
national referral centers for cancer treatment in Iran.
Inclusion criteria were; a histologically verified diagnosis
of brain cancer, older than 18 years, fluency in Persian,
and a life expectancy of at least 4 weeks. All patients
provided written informed consent. Patients with a pre-
vious cancer diagnosis, those who were too frail and
those who were unable to understand the questionnaire
or unwilling to provide written informed consent, were
excluded. The study protocol was approved by the Eth-
ical Committee of Tehran University of Medical
Sciences. All participants gave their written informed
consent.
Data collection
Patients were recruited into the study after surgery and
before chemotherapy (CT), radiotherapy (RT) or che-
moradiotherapy (CRT). Patients completed the validated
Persian version of the QLQ-C30 [13] and the Persian
version of the QLQ-BN20 before the start of the CT, RT
or CRT, and again approximately four weeks later. We
obtained sociodemographic and clinical information via
questionnaire and medical record review. This included
age, sex, education, tumor type, and surgery. Addition-
ally, the Mini-Mental State Examination (MMSE) and
The Karnofsky Performance Status Scale (KPS) were
administered to all patients.
The questionnaire was completed by interview if the
patients were illiterate. The interviewer read the ques-
tions to the patients without embellishment or explan-
ation, and presented the possible responses and elicited
patients’ choices without coaching.
Statistical analysis
Ceiling and floor effects were calculated for all QLQ-
BN20 scales. A ceiling or floor effect lower than 15%
indicates acceptable measurement standards [14].
We evaluated the scale structure of the QLQ-BN20 in
several ways. First, we used multitrait scaling to assess
item convergent and discriminant validity. We calculated
Spearman correlation coefficients between each item
and its own scale, corrected for overlap. Item-scale cor-
relations of 0.40 or greater were taken as evidence of
item convergent validity [15]. We also calculated the
Table 1 Sociodemographic and clinical characteristics of
the study sample (n = 194)*
Total






Primary school 33 (17.0%)
Middle school 36 (18.6%)














Biopsy only 40 (20.6%)
Partial resection 96 (49.5%)
Total resection 58 (29.9%)
Type of adjuvant therapy
CT 75(38.7%)
RT 62 (32%)






KPS=Karnofsky Performance Status; MMSE=Mini-Mental State
Examination.
*Patients with grade 2 and 3 tumors including, chordoid, atypical, clear cell,
rhabdoid, anaplastic (malignant) and papillary subtypes. Meningeal sarcomas
(angioblastic meningiomas) and hemangiopericytomas were also included in
the Atypical Meningioma.
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expected that items would correlate more highly (two
times the standard error, 1/√N) with their own scale
than with other scales.
Second, we used confirmatory factor analysis (CFA) to
test the hypothesized model fit. We employed three cat-
egories of indices: absolute fit indices, incremental fit in-
dices and parsimony fit indices. An absolute fit index
assesses how well an a priori model reproduces the sam-
ple data. We used chi-square, root mean square error of
approximation (RMSEA) and standardized root mean
square residual (SRMR) as absolute fit indices [16,17].
Chi-square assesses the magnitude of discrepancy be-
tween the sample and fitted covariance matrices [18].
However, the chi-square statistic is sensitive to sample
size and therefore with large samples, is not a practical
test of model fit. RMSEA incorporates a penalty function
for poor model parsimony [16]. RMSEA, values in the
range of 0.05–0.08 were taken to indicate acceptable fit,
values in the range of 0.08–0.10 to indicate marginal fit,
and values larger than 0.10 to indicate poor fit [16].
SRMR is the square root of the difference between the
residuals of the sample covariance matrix and the
hypothesized covariance model. Values of the SRMR less
than 0.10 are generally considered favorable.
We used the non-normed fit index (NNFI, also known
as the Tucker-Lewis index) and the comparative fit index
(CFI) to estimate incremental fit. The suggested cut off
for NNFI and CFI is 0.90 or greater.
We computed the parsimonious normed fit index
(PNFI) to assess the parsimony the model [17,19]. For
PNFI we did not employ any absolute standard of model
fit, but rather simply noted that higher PNFI values re-
flect more parsimonious fit [19]. We used weighted least
squares (WLS) as the method of estimation.
In addition, we examined the model invariance across
gender. To compare the factor loadings across gender,
we applied multi-group measurement invariance ana-
lysis. There are different terminologies in the literature
for tests of invariance. We used two terms of factorial
invariance (i.e., configural invariance and metric invari-
ance). In configural invariance, the pattern of fixed- and
free-factor loadings is constant across groups, while the
magnitudes of these loadings are not constrained to be
equal. For metric invariance, the magnitudes of factor
loadings for particular items are invariant across groups
[20]. As suggested by Cheung, differences in practical fit
indices such as CFI and NNFI not larger than 0.01 be-
tween NNFI or CFI values were considered as evidence
of model invariance [20]. We hypothesized that the Per-
sian version of QLQ-BN20 would perform similarly
across gender.
We estimated internal consistency reliability of the
QLQ-BN20 scales with Cronbach's coefficient alpha. Analpha coefficient of 0.70 or higher was considered ac-
ceptable for purposes of group comparisons [21].
“Known groups” or clinical validity was evaluated by
comparing the QLQ-BN20 scores between patients
grouped according to KPS and MMSE scores. We
hypothesized that patients with higher KPS (>80) would
score better on the QLQ-BN20 than those with lower
KSP (≤80) [9,10]. We also anticipated that patients with
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BN20 than those with lower MMSE (<27) [10]. Analysis
of covariance (ANCOVA) was used to test for group dif-
ferences. To control for probability of type I errors due
to multiple comparisons, we used an adjustment proced-
ure developed by Benjamini and Hochberg. This proced-
ure controls the false discovery rate. The false discovery
rate level was set at 5% [22,23]. Effect sizes (Cohen’s d
statistic) were calculated to estimate the magnitude of
observed, statistically significant group differences [24].
Finally, to evaluate the responsiveness of the QLQ-
BN20 to change in health status over time, we classified
patients as having worse, stable or improved KPS scores
from baseline to follow-up. We evaluated changes in
QLQ-BN20 scores as a function of change in KPS with
analysis of covariance (ANCOVA), adjusting for baseline
values.
We used SPSS 16.0 for Windows and LISREL 8.8 for
data analyses. A p value <0.05 was considered as statisti-
cally significant.
Results
In total, 194 patients were recruited into the study. The
patients' baseline characteristics are provided in Table 1.






BFU (future uncertainty) Baseline 194 39.9 (24.9) 8
Follow-up 187 36.8 (24.5) 10
BVD (visual disorder) Baseline 194 27.9 (26.9) 17
Follow-up 187 25.8 (25.9) 14
BMD (motor dysfunction) Baseline 194 29.0 (28.9) 28
Follow-up 186 28.6 (29.6) 23
BCD (communication deficit) Baseline 194 23.7 (27.2) 18
Follow-up 187 20.9 (25.0) 14
BHA (headaches) Baseline 192 46.9 (33.9) 25
Follow-up 187 43.6 (35.1) 21
BSE (seizures) Baseline 194 10.0 (21.6) 99
Follow-up 186 7.7 (20.0) 95
BDR (drowsiness) Baseline 192 32.2 (31.7) 28
Follow-up 185 31.2 (32.0) 19
BHL (hair loss) Baseline 194 23.8 (32.5) 41
Follow-up 187 25.9 (44.4) 38
BIS (itchy skin) Baseline 193 14.0 (25.8) 54
Follow-up 186 17.8 (27.5) 46
BWL (weakness of legs) Baseline 190 28.4 (33.9) 23
Follow-up 187 28.3 (34.1) 21
BBC (bladder control) Baseline 194 15.1 (25.8) 67
Follow-up 186 15.2 (30.3) 58range between 18 and 80 years. Forty-seven percent of
the patients was female. The majority of patients (66%)
was married, and 46% had completed secondary school
or college.
Astrocytomas (37.1%) constituted the most frequent
tumor type. Slightly more than one-third of patients
were receiving CT, one-third RT, and slightly less than
one-third CT+RT. Only seven patients (3.65%) were
lost to follow-up assessment due to death.
As shown in Table 2, all subscales of the QLQ-BN20
were found to be normally distributed (Kolmogorov-
Smirnov, p >0.05). There was no ceiling effect for any of
the BN20 subscales. However, some floor effects were
observed for seizures, headaches, itchy skin and bladder
control.
Results of the multitrait scaling analysis are presented
in Table 3. All items correlated 0.60 or higher with their
own scale, corrected for overlap. There were no scaling
errors, with all items correlating two standard errors or
higher with their own scales than with other scales.
Results of the CFA analysis indicated that all of the
goodness of fit indices supported the four-factor model
for the QLQ-BN20: χ2 = 92.51, degree of freedom= 59, p
<0.001, CFI = 1.0, RMSEA= 0.068, SRMR= 0.066,








(4.1%) 3 (1.5%) 0.80 0.14
(5.3%) 3 (1.6%) 0.74 0.24
(8.7%) 5 (2.6%) 0.74 0.16
(7.4%) 4 (2.1%) 0.80 0.15
(14.4%) 6 (3.1%) 0.80 0.46
(12.3%) 3 (1.6%) 0.82 0.18
(9.2%) 3 (1.5%) 0.89 0.21
(7.5%) 1 (0.5%) 0.89 0.22
(13.0%) 24 (12.5%) - 0.19
(11.2%) 18 (9.6%) - 0.15
(51.5%) 7 (3.6%) - 0.13
(51.0%) 1 (0.5%) - 0.11
(14.6%) 11 (5.7%) - 0.6
(10.3%) 8 (4.3%) - 0.5
(21.1%) 9 (4.6%) - 0.28
(20.3%) 10 (5.3%) - 0.06
(28.0%) 5 (2.6%) - 0.20
(24.7%) 6 (3.2%) - 0.32
(12.1%) 14 (7.4%) - 0.36
(11.2%) 12 (6.4%) - 0.29
(34.5%) 4 (2.0%) - 0.20
(31.2%) 6 (3.2%) - 0.30
Table 3 Results of the multitrait scaling analysis*
BFU BVD BMD BCD
BFU (future uncertainty)
uncertain about the future 0.75 0.15 0.04 0.19
setbacks in condition 0.62 0.06 0.10 0.28
disruption of family life 0.78 0.23 0.10 0.17
future worsen 0.67 0.21 0.18 0.04
BVD (visual disorder)
double vision 0.14 0.67 0.11 0.18
vision blurred 0.08 0.86 0.02 0.07
difficulty reading 0.16 0.83 0.10 0.05
BMD (motor dysfunction)
weakness on one side of body 0.10 0.25 0.79 0.15
trouble with coordination 0.01 0.12 0.80 0.19
feel unsteady on your feet 0.18 0.12 0.86 0.18
BCD (communication deficit)
Trouble finding the right words to
express yourself
0.14 0.21 0.11 0.88
Difficulty speaking 0.13 0.13 0.12 0.88
Trouble communicating thoughts 0.09 0.23 0.13 0.87
* Correlations are based on analysis of the baseline data.
Figure 1 Four-factor structure of the QLQ-BN20.
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ure 1). Additional analyses were based on a four-factor
model that constrained the factor loadings to be equal
across gender groups. The measurement model revealed
an acceptable model fit for the QLQ-BN20: χ2 = 190.5,
degree of freedom= 133, p <0.001, CFI = 0.923, SRMR=
0.089, NNFI = 0.911, PNFI = 0.704, RMSEA= 0.080.
Moreover, metric invariance showed good fit indices:
χ2 = 205.15, degree of freedom= 133, p <0.001, CFI =
0.927, SRMR= 0.091, NNFI = 0.915, PNFI = 0.753,
RMSEA= 0.079. These results support the stability of
the hypothesized factor structure across sexes.
The internal consistency reliability of all scales of the
QLQ-BN20 was acceptable for group comparisons
(Table 2). Cronbach's alpha coefficient for all scales was
above the 0.70 threshold. Communication deficit had
the highest internal consistency (0.89 at both baseline
and follow-up) while the lowest was for future uncer-
tainty (0.80, 0.74).
Results from the known group comparisons between
subgroups of patients formed on the basis of perform-
ance status and MMSE are summarized in Table 4. As
hypothesized, patients with better KPS and MMSE
Table 4 Known groups validity testing: Comparison of QLQ-BN20 Scores as a function of KPS and MMSE
KPS Effect size MMSE** Effect size
>80 ≤80 <27 ≥27
N=91 N=103Baseline N=53, N= 141,
Follow-up N=41 N=153
BFU (future uncertainty) Baseline*{ 42.7 (22.2) 33.5 (24.7) 0.38 33.9 (24.4) 27.2 (23.4) 0.28
Follow-up * 37.0 (15.1) 25.6 (24.5) 0.50 - - -
BVD (visual disorder) Baseline *{ 38.3 (30.1) 27.0 (27.3) 0.40 28.1 (29.4) 21.8 (22.8) 0.24
Follow-up * 33.3 (27.8) 23.7 (26.1) 0.36 - -
BMD (motor dysfunction) Baseline*{ 68.2 (31.8) 24.6 (26.3) 1.56 33.7 (30.2) 16.5 (22.5) 0.65
Follow-up * 63.9 (29.1) 22.4 (27.0) 1.5 - -
BCD (communication deficit) Baseline *{ 44.9 (31.9) 20.3 (26.5) 0.88 26.1 (28.3) 14.1 (21.8) 0.48
Follow-up* 45.0 (33.4) 17.0 (22.6) 1.11 - -
BHA (headaches) Baseline *{ 50.0 (36.0) 44.3 (32.2) 0.17 47.8 (28.6) 34.8 (34.4) 0.41
Follow-up * 63.3 (36.7) 42.5 (35.1) 0.59 - -
BSE (seizures) Baseline *{ 15.1 (22.9) 11.0 (23.3) 0.18 14.3 (25.5) 5.7 (15.6) 0.41
Follow-up * 14.8 (24.2) 8.5 (21.2) 0.29 - -
BDR (drowsiness) Baseline *{ 57.6 (30.1) 28.3 (31.2) 0.95 34.7 (33.3) 22.3 (25.0) 0.42
Follow-up * 66.7 (27.2) 26.6 (30.5) 1.34 - -
BHL (hair loss) Baseline*{ 33.3 (35.1) 22.1 (32.2) 0.34 23.4 (32.8) 16.8 (33.5) 0.20
Follow-up* 63.3 (36.7) 42.5 (35.1) 0.59 - -
BIS (itchy skin) Baseline*{ 33.3 (35.1) 13.2 (24.7) 0.72 19.2 (30.4) 9.2 (17.6) 0.41
Follow-up* 40.0 (37.8) 16.5 (26.5) 0.80 - -
BBC (bladder control) Baseline*{ 45.4 (37.3) 12.8 (24.2) 1.15 19.0 (27.3) 9.2 (23.4) 0.39
Follow-up* 50.0 (42.3) 12.9 (28.2) 0.97 - -
* Statistically significant for KPS.
{ Statistically significant for MMSE.
** MMSE was only available at baseline.
Table 5 Changes of QLQ-BN20 over time by performance
status
KSP
Worsening Stable Improved P value
(ANCOVA)N=59 N=49 N=79
Mean (SD) Mean (SD) Mean (SD)
*
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BN20 multi-item scales than patients with lower KPS
and MMSE scores. Effect sizes (Cohen’s d statistic) ran-
ged from 0.18 to 1.56 for the KPS, and from 0.20 to 0.65
for the MMSE.
Finally, changes in QLQ-BN20 scores over time as a
function of changes in KPS scores (worse, stable or
improved performance status) are reported in Table 5.
The results supported the ability of all of the QLQ-
BN20 scales to detect such shifts in KPS, with the excep-
tion of seizures, drowsiness, visual disorder and hair loss
which did not vary as a function of change in KPS.Headaches 12.4 (29.2) 1.2 (35.4) -10.0 (32.6) 0.04
Motor dysfunction* 6.1 (18.8) 0.1 (18.2) -4.3 (15.4) 0.01
Drowsiness 5.5 (23.2) 2.4 (27.3) 1.7 (24.3) 0.38
Weakness of legs*† 15.2 (28.4) -1.3 (20.2) -12.1 (19.3) <0.01
Visual disorder 5.4 (16.1) 2.7 (25.4) 1.6 (22.3) 0.64
Bladder control*† 9.6 (18.8) -0.7 (28.9) -6.6 (26.3) 0.01
Seizures 5.3 (19.8) 3.2 (21.8) 2.7 (17.6) 0.72
Hair loss 12.4 (29.2) -4.5 (50.4) -15.2 (45.4) 0.08
Itchy skin* 6.5 (20.8) 0.4 (26.4) -3.8 (24.8) 0.02
* P< 0.05 Improved Vs. Worsening Group.
† P< 0.05 Stable Vs. Worsening Group.Discussion
In this paper we have reported on the results of the
translation and validation of the Persian version of the
QLQ-BN20 for use with primary brain cancer patients
in Iran. This included examination of the hypothesized
scale structure of the questionnaire, internal consistency
reliability estimation, known groups validity testing, and
evaluation of the responsiveness of the QLQ-BN20 to
changes over time in health status.Overall, the results lend strong support to the psycho-
metric robustness of the questionnaire. The large major-
ity of patients completed all items and there were very
minor missing items. Ceiling effects were absent while
Khoshnevisan et al. Health and Quality of Life Outcomes 2012, 10:54 Page 7 of 8
http://www.hqlo.com/content/10/1/54some floor effects were observed for items assessing sei-
zures, hair loss, itchy skin and bladder control. A pos-
sible reason for this latter finding could be that most of
the patients were newly-diagnosed and had only recently
initiated adjuvant treatment. With longer follow-up,
more variance in scores for these symptoms could be
expected. Our results are in accordance with previous
studies [9,10].
The results of both the mulitrait scaling and CFA pro-
vided strong support for the hypothesized scale structure
of the QLQ-BN20. To our knowledge, ours is the first
study to employ CFA in the evaluation of the QLQ-
BN20 measurement model. Some studies have reported
that females with brain tumors tend to report worse
QOL than their male counterparts [25-27]. It is import-
ant to determine if these gender differences also affect
the scale structure of the questionnaire. [28]. Toward
this end, we assessed the factorial invariance of the
QLQ-BN20. The results of the CFA demonstrated that
the hypothesized four-factor model fit the data of both
the male and female samples well, supporting invariance.
To our knowledge, ours is the first study to assess factor
structure of the QLQ-BN20 for patients with primary
brain tumours using confirmatory factor analysis We
would recommend that this be undertaken in other cul-
tural and language settings as well.
The internal consistency reliability of the QLQ-BN20
scales exceeded the recommended 0.70 level, with most
coefficients in the 0.80 to 0.90 range. These reliability
estimates are even higher than those reported in previ-
ous studies with English-speaking and multi-national
samples [9,10].
The QLQ-BN20 was able to distinguish clearly between
subgroups of patients formed on the basis of their per-
formance status and cognitive status, and was responsive
to change over time in performance status. Again, these
results are in line with those of previous studies [9,10].
Our study had several limitations that should be
noted. First, we recruited a convenience sample of
patients. Nevertheless, we believe that the sample suffi-
ciently represents the population of interest. Second, al-
though the overall sample size was sufficient for the
analyses that we conducted, there were insufficient num-
bers available to carry out subgroup analyses of more
homogenous groups of brain cancer patients. This is
something that could be done in future studies. Finally,
the study was of relatively short duration, and thus we
had a relatively short period evaluate the responsiveness
of the QLQ-BN20 over time. Use of the questionnaire in
large, prospective studies should provide the opportunity
to examine the responsiveness of the questionnaire over
long periods of time.
In conclusion, the results of our study support the
feasibility, measurement model, reliability and validitythe QLQ-BN20 in assessing the HRQOL of Iranian
patients with primary brain cancer. The availability of
this questionnaire in Persian will facilitate the assess-
ment of the health-related quality of life of brain cancer
patients in Iran, particularly in the context of clinical re-
search, but also potentially in clinical practice setting.
Future studies are needed to examine the psychometric
properties of the Iranian version of the QLQ-BN20
among patients with brain metastases.
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